Roivant Sciences Ltd (ROIV)
Market Closed
17 Jul, 20:00
$
34. 51
+0.58
+1.7094%
$
25.11B Market Cap
- P/E Ratio
- Div Yield
3.83M Volume
- Eps
$ 33.93
Previous Close Want to track ROIV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ROIV closed Friday higher at $34.51, an increase of 1.7094% from Thursday's close, completing a monthly increase of 18.3471% or $5.35. Over the past 12 months, ROIV stock gained 58.959%.
ROIV is not paying dividends to its shareholders.
The last earnings report, released on Jun 04, 2026, exceeded the consensus estimates by 0.26%. On average, the company has surpassed earnings expectations by 0.2267%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Seekingalpha | 1 month ago
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Seekingalpha | 2 months ago
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Zacks | 2 months ago
Roivant Sciences Ltd Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 194 | $3,748.48 | $6,694.94 | $2,946.46 | 78.6% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 300 | $6,510 | $10,353 | $3,843 | 59.03% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 67 | $1,453.9 | $2,312.17 | $858.27 | 59.03% |
 Farallon Capital Farallon Capital Management LLC | 9.68M | $267.39M | $333.88M | $66.5M | 24.87% |
| BG Bart Gancher Intech Investment Management LLC | 45,238 | $1.25M | $1.56M | $308,070.78 | 24.58% |
Roivant Sciences Ltd (ROIV) FAQ
What is the stock price today?
The current price is $34.51.
On which exchange is it traded?
Roivant Sciences Ltd is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is ROIV.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 25.11B.
Has Roivant Sciences Ltd ever had a stock split?
No, there has never been a stock split.
Roivant Sciences Ltd Profile
| Biotechnology Industry | Healthcare Sector | Matthew Gline CEO | NASDAQ (NGS) Exchange | G76279101 CUSIP |
| GB Country | 721 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company with a focus on the development and commercialization of innovative medicines primarily within the inflammation and immunology sectors. With its unique model, known as Vants, Roivant aims to efficiently develop and bring to market its therapeutic technologies and medicines. This model collaborates with biopharmaceutical businesses, discovery-stage companies, and health technology startups. Founded in 2014 and headquartered in London, the United Kingdom, Roivant Sciences has established strategic collaborations and licensing agreements with industry leaders such as Boehringer Ingelheim International, GmbH, and Japan Tobacco Inc., to enhance its discovery and development efforts across a range of therapeutic areas.
Products and Services
- VTAMA: A novel topical medication approved for the treatment of psoriasis, and currently under development for the treatment of atopic dermatitis. VTAMA represents Roivant’s foray into dermatological treatments, highlighting their commitment to addressing skin conditions with innovative solutions.
- IMVT-1402 and batoclimab: These are fully human monoclonal antibodies targeting the neonatal Fc receptor, with development spanning various IgG-mediated autoimmune diseases. These innovative treatments exemplify Roivant’s approach to tackling autoimmunity through targeted antibody therapies.
- brepocitinib: A dual inhibitor of TYK2 and JAK1, brepocitinib is in development for multiple inflammatory conditions, including dermatomyositis and non-infectious uveitis. This potent small molecule underscores Roivant’s commitment to developing therapies that modulate the immune system to treat diseases.
- Namilumab: As a fully human anti-GM-CSF monoclonal antibody, Namilumab is currently under a Phase 2 clinical trial, targeting a range of inflammatory and autoimmune disorders. This treatment option further represents Roivant’s focus on novel immune-modulating therapeutic agents.
- Delivery Platforms: Roivant is working on enhancing drug delivery mechanisms, including a lipid nanoparticle platform and a ligand conjugate platform. These platforms are part of Roivant’s broader strategy to improve the efficacy and delivery of treatments.
- Collaborations: The company has forged significant partnerships, notably with Boehringer Ingelheim International, GmbH for the development of RNA-targeting compounds, and with Japan Tobacco Inc., securing the rights to develop, register, and market tapinarof in Japan for psoriasis and atopic dermatitis. These collaborations are vital to Roivant’s strategy of leveraging external expertise and markets to broaden its therapeutic impact.
Contact Information
Address: 11-12 St. James's Square
Phone: 44 2074 003 347
Website: https://roivant.com
